PTI-1

PTI-1
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name N,N-diethyl-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)ethanamine;
JSmol)	Interactive image;
	SMILES CCCCCN1C=C(C2=NC(CN(CC)CC)=CS2)C3=CC=CC=C31.Cl;
	InChI InChI=1S/C21H29N3S.ClH/c1-4-7-10-13-24-15-19(18-11-8-9-12-20(18)24)21-22-17(16-25-21)14-23(5-2)6-3;/h8-9,11-12,15-16H,4-7,10,13-14H2,1-3H3;1H; Key:NPYOTZAJIONLKZ-UHFFFAOYSA-N;

PTI-1 (SGT-48) is an

Organon and subsequently further researched by Merck.^[2]^[3]^[4]

References

^ "PTI-1". Cayman Chemical. Retrieved 8 July 2015.
^ US 7700634, Adam-Worrall J, Morrison AJ, Wishart G, Kiyoi T, McArthur DR, "(Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor.", issued 20 April 2010, assigned to Organon NV
^ US 7763732, Paul David Ratcliffe PD, Adam-Worrall J, Morrison AJ, Francis SJ, Kiyoi T, "Indole Derivatives", issued 27 July 2010, assigned to Organon NV
PMID 21316962
.

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=PTI-1&oldid=1082426145"